Literature DB >> 25483461

Sero-surveillance to assess rubella susceptibility and assessment of immunogenicity and reactogenicity of rubella vaccine in Indian girls aged 18-24 years.

Deepak S Phalgune1, Rajiv C Yervadekar, Hitt J Sharma, Rajeev M Dhere, Sameer S Parekh, Alka O Chandak, Abhijeet A Safai, Sunil D Shewale.   

Abstract

Rubella infection though a mild infection, may cause foetal death or a variety of congenital anomalies. Multiple sero-surveys confirmed that 5-10% women are unexposed to natural or vaccinated rubella virus and remain susceptible to rubella infection. The current study was conducted in 600 girls, aged 18-24 y from Symbiosis International University (SIU), Pune, India to assess their sero-status against rubella infection and to estimate the immunogenicity of rubella vaccine in achieving sero-protective antibody titres. Prior to administration of a single i.m. dose of rubella vaccine (R-vac®) to eligible participants, blood sample (pre-vaccination) was collected. During the 4-6 weeks observation period, adverse events were noted. Then, a second blood sample (post-vaccination) was collected. Significant increase was noted in sero-protection response, viz., 98.6% (post-vaccination) vis-à-vis 66.5% (pre-vaccination); Geometric mean titer (GMT) was significantly higher post-vaccination. Effective measures to introduce rubella vaccination on a larger scale need to be undertaken. An immunization policy with mandatory rubella vaccination for all girls in the reproductive age group and its inclusion in national immunization schedule is highly desirable.

Entities:  

Keywords:  CRS, congenital rubella syndrome; GMT, geometric mean titer; India; immunogenicity; rubella; safety; sero-survey

Mesh:

Substances:

Year:  2014        PMID: 25483461      PMCID: PMC5443094          DOI: 10.4161/21645515.2014.970947

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  22 in total

1.  Candidate viral diseases for elimination or eradication.

Authors:  F Fenner
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

2.  Seroprevalence of rubella and immunogenicity following rubella vaccination in adolescent girls in India.

Authors:  Hitt J Sharma; Vasant S Padbidri; Subhash V Kapre; Suresh S Jadhav; Rajeev M Dhere; Sameer S Parekh; Ashok D Dudhane; Sunil D Shewale; Gajanan S Namjoshi
Journal:  J Infect Dev Ctries       Date:  2011-12-13       Impact factor: 0.968

3.  The history of rubella and rubella vaccination leading to elimination.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2006-11-01       Impact factor: 9.079

4.  Congenital rubella syndrome: the end is in sight.

Authors:  Scott R Lambert
Journal:  Br J Ophthalmol       Date:  2007-11       Impact factor: 4.638

5.  Rubella vaccines: WHO position paper.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2011-07-15

6.  Serological investigation of rubella virus infection in and around Chandigarh--a preliminary communication.

Authors:  S R Pal; N L Chitkara; S Broor; J G Murthy; S Choudhury; P K Devi
Journal:  Indian J Med Res       Date:  1974-02       Impact factor: 2.375

7.  Serological study for the prevalence of rubella at Lucknow.

Authors:  A Mathur; U C Chaturvedi; R M Mehrotra
Journal:  Indian J Med Res       Date:  1974-02       Impact factor: 2.375

8.  Infectious aetiology of congenital cataract based on TORCHES screening in a tertiary eye hospital in Chennai, Tamil Nadu, India.

Authors:  B Mahalakshmi; K Lily Therese; U Devipriya; V Pushpalatha; S Margarita; H N Madhavan
Journal:  Indian J Med Res       Date:  2010-04       Impact factor: 2.375

9.  Rubella serosurveys at three Aravind Eye Hospitals in Tamil Nadu, India.

Authors:  Perumalsamy Vijayalakshmi; Rajamanickam Anuradha; Karthik Prakash; Kalpana Narendran; Meenakshi Ravindran; Lalitha Prajna; David Brown; Susan E Robertson
Journal:  Bull World Health Organ       Date:  2004-04       Impact factor: 9.408

10.  The opportunity and obligation to eliminate rubella from the United States.

Authors:  W A Orenstein; K J Bart; A R Hinman; S R Preblud; W L Greaves; S W Doster; H C Stetler; B Sirotkin
Journal:  JAMA       Date:  1984-04-20       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.